glp 1 gip glucagon triple agonist Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Retatrutide: How Triple GLP-1/GIP/Glucagon Receptor

Most DPP-4 inhibitors require dose reduction or avoidance in moderate-to-severe renal impairment, and prescribers should consult the relevant Summary of Product Characteristics

Definition, epidemiology and classification of diabetes in children and adolescents

Neurogastrx is studying the peripherally acting dopamine D2/D3 receptor antagonist investigational drug, metopimazine, for reducing the incidence, duration and severity of nausea and vomiting in individuals who received a single SC dose of semaglutide

doi: 10.1038/s41591-021-01584-3 [DOI] [PubMed] [Google Scholar] 95

& Trujillo, J

Both pathways can be medically appropriate depending on patient access, cost, provider preference, and clinical context